PubMed Health⌕ Search

Biomedical subjects

A Lypka

Publications and source records attributed to A Lypka.

13 recordsLinked to original sources
PubMed1992

The prognostic value of prostate-specific antigen and prostatic acid phosphatase in serum of patients with prostate cancer after orchidectomy.

Correlations between the serum levels of PAP and PSA before and 1, 3 and 6 months after orchidectomy in 27 prostatic cancer patients (advanced clinical stages C and D according to Whitemore scale) were studied. The PSA values correlated more distinctly than PAP with the general clinical condition. PSA is a reliable tumour marker when used at regular intervals, especially for monitoring therapeutic results. A high preoperative PSA level correlates with a high postoperative level and progression of the disease.

Acid Phosphatase↗
PubMed1991

[Serum angiotensin converting enzyme (SACE) in patients with atopic bronchial asthma].

The aim of the study was to assess serum ACE (S-ACE) activity in atopic bronchial asthma. S-ACE activity values were determined in 50 subjects (11 blood donors, 39 asthmatics) using the radioenzymatic method with Ventrex Laboratories kits. The authors did not find any differences between asthmatics in clinical remission, not receiving therapy, patients receiving prednisone (mean daily dose 10.0 +/- 2.5 mg) and healthy blood donors. In subjects with exacerbations of bronchospasm (not receiving steroids) S-ACE activity was significantly higher.

Adult↗
PubMedDate not supplied

[Three month treatment with budesonide in patients with corticoid dependent bronchial asthma--personal experience].

The experiment aimed at evaluating a three-month therapy of asthmatic patients with budesonide inhalations. The study involved 32 patients with long-lasting bronchial asthma depended on steroids. Therapy with budesonide (Pulmicort Astra) in a mean daily dose 1.6 mg enabled withdrawal of depot steroids and inhalation treatment only. In patients receiving prednisone in a mean daily dose 5.0 +/- 4.8 mg, budesonide therapy enabled a reduction of the oral dose by 50 percent. A significant improvement in the psychophysical status of patients has been noted despite a lack of significant differences in the results of lung functioning tests. Adverse reactions such as relaxation, insufficiency of the vocal cords at phonation and hoarseness were seen in 20 percent of patients, and in one of them required cessation of the drug. An increase in the number of Candida albicans colonies in throat swabs (over 20 colonies per plate) was seen in 7 treated patients but clinical symptoms which required an additional treatment were noted only in 1 patient.

Adult↗
PubMedDate not supplied

[Evaluation of the bioavailability of Polfa phenytoin tablets].

Bioavailability of Phenytoin "Polfa" tablets was studied in comparison with Epanutin "Parke-Davis" capsules. It was found that the relative degree of bioavailability of Phenytoin in relation to Epanutin as a standard is 70,7 +/- 6,3% (SD). The cause of worse bioavailability of Phenytoin "Polfa" are differences in pharmaceutical forms of both preparations. The necessity to increase an average dose of Phenytoin "Polfa" tablets is suggested to gain optimal concentration of diphenyl-hydantoin in serum, in therapeutic range.

Adult↗